APA (7th ed.) Citation

J, K., W, F., RF, S., P, P., F, T., M, L., . . . M, H. (2018). Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial). British journal of haematology, 183(2), 235. https://doi.org/10.1111/bjh.15546

Chicago Style (17th ed.) Citation

J, Krauter, et al. "Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Newly Diagnosed Patients with Acute Myeloid Leukaemia and High Risk for Induction Failure (AMLSG 17-10 CIARA Trial)." British Journal of Haematology 183, no. 2 (2018): 235. https://doi.org/10.1111/bjh.15546.

MLA (9th ed.) Citation

J, Krauter, et al. "Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Newly Diagnosed Patients with Acute Myeloid Leukaemia and High Risk for Induction Failure (AMLSG 17-10 CIARA Trial)." British Journal of Haematology, vol. 183, no. 2, 2018, p. 235, https://doi.org/10.1111/bjh.15546.